Skip to main content

CITADEL ADVISORS LLC

Position in BCAX — Bicara Therapeutics Inc.

CIK 1423053 MIAMI, FL

Position in BCAX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$33,004,311
+$20,007,210 QoQ
Shares Held
1,659,342
+114.9% QoQ
Ownership
2.53%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Sep 2024
4 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in BCAX Over Time

Shares Held

Position Value (USD)

Derivatives in BCAX

reported options exposure · as of Mar 31, 2026
CallValue
$202,878
CallShares
10,200
PutValue
$1,127,763
PutShares
56,700

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. BCAX ranks #39 (0.6% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in BCAX

Export CSV
7 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $1,127,763 56,700
2026-03-31 $202,878 10,200
2026-03-31 $33,004,311 1,659,342
2025-12-31 $414,018 24,600
2025-12-31 $12,997,101 772,258
2025-06-30 $2,057,883 221,516
2024-09-30 $5,963,087 234,122